Evidence map›Paper›PMID 42814337›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2027

High-Dimensional Multimodal Data Integration for Immune-Driven Diseases: A Practical Guide.

Emiko Desvaux, Amazigh Mokhtari

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Emiko DesvauxBiomarker Data Analytics, Sanofi, 9 Quai Jules Guesde, 94400, Vitry-sur-seine, France. emiko.desvaux@sanofi.com.
Amazigh MokhtariBiomarker Data Analytics, Sanofi, 9 Quai Jules Guesde, 94400, Vitry-sur-seine, France. Amazigh.mokhtari@sanofi.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent advances in multiomics technologies have revolutionized the study of immune-driven diseases by enabling high-dimensional, single-cell resolution analyses. This chapter provides a practical guide for integrating CyTOF (mass cytometry) and single-cell RNA sequencing (scRNA-seq) data to address key challenges in this field. The integration of these modalities allows for consistent and reproducible cell type annotation, the transfer of annotations to assist in characterizing difficult-to-identify populations, and the transcriptional characterization of rare and heterogeneous subpopulations. Using tools such as OMIQ and R, the chapter outlines workflows for preprocessing, normalization, and scaling of CyTOF data, as well as dimensionality reduction and clustering techniques. The integration process involves creating Seurat objects, identifying common features, and using anchor-based methods to link CyTOF and scRNA-seq datasets. The chapter also discusses the use of multimodal deep learning techniques for rare subpopulation detection and emphasizes the importance of reproducibility and standardization in multiomics integration. By leveraging these methodologies, researchers can gain deeper insights into cellular heterogeneity and function, ultimately enhancing the understanding of immune-driven diseases. The chapter concludes by addressing integration challenges and proposing future directions for improving model interpretability and capturing nonlinear molecular interactions.

Indexed as

Computational BiologyImmune System DiseasesSingle-Cell AnalysisAnimalsClustering AlgorithmsDeep LearningFlow CytometryHumansMultiomicsRNA-SeqSingle-Cell Gene Expression AnalysisSoftwareCyToF scRNA-seqData integrationImmuno-driven diseasesMultiomics

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.